A battery of wild-type, mutated p53-expressing or p53-null human cancer cells from different origins e.g., colon cancer (HCT116: p53+/+, p53−/− and HT29: p53mt), breast cancer (MCF-7: p53+/+ and MDA-MB-231: p53mt) were selected to study the effect of crocetin. Here, TP53 is linked to colonic neoplasm.